What are FDA recall classes I, II and III, and how does a recall differ from a market withdrawal, stock recovery or correction?

FDA assigns the class after its own health hazard evaluation. Class I: a reasonable probability of serious adverse health consequences or death. Class II: temporary or medically reversible harm, or a remote probability of serious harm. Class III: harm is not likely. Only recalls are classified, whether they remove product or correct it where it is. A market withdrawal removes product with a minor violation or none, and a stock recovery retrieves product that never left the firm’s control.

FDA recall classes I, II and III, with real examples

1Recall, market withdrawal, stock recovery or correction?

Two questions separate them. Has any of the lot left the firm’s direct control? If not, it is a stock recovery. If it has, would FDA take legal action, such as seizure, against the product? If so, removing or correcting it is a recall, whatever the firm calls it; if not, it is a market withdrawal.¹ ²

Table 1. Recall, market withdrawal and stock recovery as 21 CFR 7.3 defines them, and correction, a method any of them can use. The market withdrawal example is FDA’s; the recall example is one FDA’s public warning guidance names.¹ ³ ⁴ ⁵

Action	What it is	Classified?	In the Enforcement Report?	Example
Recall	Removal or correction of marketed product FDA considers violative and would take legal action against	Yes: Class I, II or III	Yes	Sterile injection with particulate matter
Correction	Repair, modification, adjustment, relabelling, destruction or inspection, including patient monitoring, without moving the product	Yes, when it is a recall	When it is a recall	Relabelling stock where it sits
Market withdrawal	Removal or correction for a minor violation FDA would not act on, or no violation	No	No	Removal after tampering with no manufacturing or distribution problem
Stock recovery	Product never marketed, or still under the firm’s direct control with no part of the lot released	No	No	A failing batch still in the firm’s own warehouse

A firm that believes a removal is only a market withdrawal should consult FDA when the reason is unclear but complaints or adverse reactions show the product is deficient.² In the EU, a quality defect leaves no such middle category: “After a product has been placed on the market, any retrieval of it from the distribution network as a result of a quality defect should be regarded and managed as a recall.”⁶ Device makers also report to FDA corrections and removals made to reduce a risk to health, or to remedy a violation that may present one, “within 10-working days” of starting them, under Part 806; see device corrections and removals.⁷

2Class I, II and III.

FDA assigns the class after evaluating the health hazard, and the same three classes apply to every product Part 7 covers: “any food, drug, and device”, biologics, cosmetics and tobacco products among them. The definitions in 21 CFR 7.3(m):¹

Class I: “a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death.”
Class II: “a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.”
Class III: “a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.”

Table 2. One real drug Enforcement Report entry for each class, as openFDA lists them.⁸

Class	Recall number	Product	Reason, as FDA lists it	Reported
Class I	D-0788-2026, Fresenius Kabi USA	Morphine Sulfate Injection, 2 mg/mL prefilled syringes	“Labeling: Label Mixup: MicroVault labeled as Morphine 2 mg/1 mL, contains a Prefilled Syringe of Dilaudid 0.5 mg/0.5 mL.”	26 Aug 2026
Class II	D-0079-2027, Strides Pharma	Cinacalcet Tablets, 30 mg, 30-count bottles	“Failed dissolution specifications”	28 Oct 2026
Class III	D-0713-2026, Asclemed USA	Lidolog Kit, lidocaine HCl injection 2%	“Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan”	29 Jul 2026

Table 3. What usually follows each class.⁹ ¹⁰ ⁵

Class	Typical depth	Letter and envelope marked	Public warning
Class I	Consumer or user	Drug recall, urgent	FDA generally issues or seeks one
Class II	Retail	Drug recall, urgent	In some urgent cases
Class III	Wholesale	Drug recall; urgent when appropriate	Not addressed in the guidance

FDA’s manual gives the depths as a general pattern; strategies “are not necessarily dependent on the recall classification.”⁹ When FDA says a public warning is appropriate, firms “should generally issue a public warning within 24 hours”.⁵

3How FDA classified drug recalls, 2024 to 2026.

Table 4. Drug Enforcement Report entries dated 1 January 2024 to 28 October 2026 whose recall reason contains the phrase: particulate matter, lack of assurance of sterility, failed dissolution, failed impurities, nitroso, microbial or labeling. Rows overlap, one recall can have several product entries, and openFDA says to “assume all results are unvalidated”.¹¹

Reason in the report	Class I	Class II	Class III
Particulate matter	31	104	1
Lack of assurance of sterility	2	362	0
Failed dissolution	3	76	5
Failed impurities	0	68	42
N-nitroso	0	158	0
Microbial	29	35	0
Labeling	21	22	37
All drug entries	193	1,749	183

Class II is the usual outcome: 1,749 of 2,126 entries, with one not yet classified. By report date, drug Class I entries numbered 106 in 2024, 49 in 2025 and 38 in 2026 to 28 October, from 46, 29 and 34 distinct recall events (openFDA’s event_id).¹¹ The reason alone does not decide the class. Particulate matter and labelling appear in all three, because FDA weighs each product’s hazard: who is exposed, how serious the harm would be and how likely it is.¹¹ ¹² FDA also starts from precedent: “Precedent HHEs will be used where the product is identical or similar with basically the same defect or violation as a recall action previously classified.” That helps explain why most entries for one reason share a class.⁹

4Who classifies, and how fast.

A firm recalling on its own initiative is asked to notify the FDA district “immediately”, with the nine items in the checklist below, and need not wait for FDA before starting.² FDA then runs its own health hazard evaluation against the six factors in 7.41(a), within two working days of receiving a recall recommendation unless it needs more information, and its recall unit normally classifies within two days of that evaluation. Until then the Enforcement Report lists the recall as “not yet classified”.⁹ In the three examples above, FDA classified the recalls 20, 19 and 5 days after the firms began them.⁸ Your proposed class informs FDA; it does not bind it.¹ ¹²

5Health hazard evaluation template, worked to a proposed class.

The rows are the six 7.41(a) factors, scored on the hazard and probability scales of FDA’s own worksheet, then two worksheet questions that shape the strategy.¹² ⁹ The example is invented: 12-month stability dissolution on distributed Exemplol 10 mg tablets, Batch 25-044, an ANDA product for a chronic condition, is 68% at 30 minutes against a limit of not less than 80%. The batch was 1,600 bottles of 30, shipped to 4 wholesalers that supplied 212 pharmacies.

Table 5. Example. Product, batch, complaints and assessment are invented for illustration.

Factor	What it asks	Example answer
1. Harm so far	Has disease or injury already occurred?	Two complaints of reduced effect, no injuries reported
2. Contributing conditions	Could existing conditions create a hazard?	Patients near the edge of control may lose control for some days
3. Who is exposed	Which segments, and who is at greatest risk?	Older patients taking several medicines
4. Seriousness	How serious is the hazard?	Temporary or reversible, on FDA’s worksheet scale
5. Likelihood	How likely is it to occur?	Remote for serious harm
6. Consequences	Immediate or long-range?	Immediate and short-lived; none long-range expected
Obvious to the user?	Is the problem easily identified by the user?	No: low dissolution cannot be seen
Supply	Would removal disrupt treatment?	No: other makers supply the same strength
Proposed class	Which 7.3(m) definition fits?	Class II: temporary or medically reversible
Strategy	Depth, warning, checks	Retail depth; no public warning; Level C checks

At retail depth there are 216 consignees, the 4 wholesalers and 212 pharmacies. Level C means contacting 10% of them: 21.6, so 22 checks.¹³ FDA’s own pattern fits the proposal: 76 of 84 failed-dissolution entries since 2024 were Class II.¹¹ The same result also needs a Field Alert Report within 3 working days, because a distributed ANDA batch failed its specification.¹⁴

5.1Recall records checklist.

What FDA asks the recalling firm for, line by line.

Notification to the district, 7.46(a):²

(1) Identity of the product.
(2) Reason for the removal or correction, and the date and circumstances of discovery.
(3) Your evaluation of the risk: the HHE above.
(4) Total amount produced, or the timespan of production.
(5) Amount estimated to be in distribution.
(6) Distribution information, including the number of direct accounts.
(7) The recall communication, issued or proposed.
(8) The proposed recall strategy.
(9) Name and telephone number of the firm’s contact.

Recall letter, 7.49(b) and (c):¹⁰

(b) Marked on letter and envelope as a drug recall, and “urgent” for Class I and II and, when appropriate, Class III.
(c)(1)(ii) Product, size, lot numbers, codes or serial numbers.
(c)(1)(iii) The reason for the recall and the hazard.
(c)(1)(iv) Specific instructions on what to do with the product.
(c)(1)(v) A ready means to report whether the recipient has any.
(c)(2) No irrelevant qualifications or promotional material; follow-ups to non-responders.

Status report, 7.53(b), generally every 2 to 4 weeks:¹⁵

(1) Consignees notified, with the date and method.
(2) Consignees responding, and the quantity they had on hand.
(3) Consignees that did not respond.
(4) Quantity returned or corrected by each consignee contacted.
(5) Number and results of effectiveness checks.
(6) Estimated time to complete the recall.

Status reports continue until FDA terminates the recall, which it does when it is reasonable to assume the product has been removed or corrected in proportion to the hazard. The firm may ask for termination in writing, with its latest status report and how recalled product was disposed of.¹⁵ ¹⁶

6What inspectors check.

For drugs, recall readiness is a CGMP requirement: 21 CFR 211.150(b) requires distribution procedures to include “A system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary.”¹⁷ EU GMP asks that recall operations can start “promptly and at any time”, that each recall closes with a final report including “a reconciliation between the delivered and recovered quantities”, and that recall arrangements are periodically evaluated, out of hours too, considering whether mock recalls are needed.⁶ Part 7’s general industry guidance, 7.59, suggests a written contingency plan, product coding, and distribution records kept beyond the product’s shelf life and expected use.¹⁸

When an investigator learns of a recall FDA has no record of, FDA’s 2026 Investigations Operations Manual says to collect the recall communications, with scripts of phone calls to consignees, the complete distribution list including foreign distribution, and the labels, and to check that the firm’s recall procedures include notifying FDA. An unreported market withdrawal goes to the division recall coordinator, who can ask the center’s recall unit to confirm the designation.¹⁹ Not knowing where recalled batches went is cited too:

“Despite being notified of (b)(4) contamination in your product, your firm failed to determine whether the recalled batches were also distributed in the United States and did not evaluate the potential risk to U.S. consumers.”

The customer had recalled the batches in Canada. kdc/one Chatsworth, Inc., warning letter 320-26-124, 8 September 2026.²⁰

An HHE is judged on its evidence. A device maker concluded that no recall was needed after acknowledging particulate contamination in its bone void fillers:

“HHE-(b)(4) concluded that no correction, removal, or recall recommended, as the risk level assessed as Low and Acceptable. Your firm acknowledges that (b)(4) contamination occurred from 2008-2024, with over (b)(4) devices potentially affected, however no actual testing was performed to confirm the absence of (b)(4) in distributed product.”

FDA also faulted a severity rating of Moderate when the firm’s complaint data “includes revision surgery, hospitalization, IV antibiotics, osteolysis consistent with a higher severity rating as noted in your procedure.” IsoTis OrthoBiologics, Inc., warning letter CMS #723370, 24 February 2026.²¹

A recall FDA wants can still be the firm’s own. After inspecting an aseptic injectables plant, FDA wrote:

“On March 26, 2026, FDA held a teleconference with you recommending you recall epinephrine injection USP 0.1 mg/mL lot EA038A5 from the U.S. market.”

The firm began a voluntary recall on 1 April 2026, for lack of sterility assurance. International Medication Systems Limited, warning letter 320-26-99, 2 July 2026.²²

7EU and UK recall classes.

Table 6. Recall classes compared.¹ ²³ ²⁴

Class	FDA	EU	MHRA
I or 1	Reasonable probability of serious harm or death	Potentially life-threatening; to patient level when needed	Risk of death or disability; a National Patient Safety Alert
II or 2	Temporary or reversible harm, or remote serious harm	Could cause illness or mistreatment; normally to pharmacy level	May cause mistreatment or harm, not life-threatening or serious
III or 3	Harm not likely	May not pose a significant hazard; normally to wholesalers	Unlikely to cause harm; recalled for other reasons
4	None	None	Caution in Use notice, not a recall

In the EU, the authority classifies a quality defect as high, moderate or low risk within 1 working day of a complete report, and starts managing it within 3, 5 or 10 working days, the last optional. These timelines arrived in the procedure’s revision adopted on 20 April 2026.²³ A Class I rapid alert goes to every authority in the Rapid Alert Network whether or not the batch was exported there; Class II goes to the countries supplied; Class III recalls are not sent as rapid alerts.²³ Class I alerts, and Class II where feasible, go out with the national action and within 24 hours of it.²⁵ MHRA’s Class 4 is used for minor packaging or printed material defects, or where supply concerns mean a defective product cannot be recalled.²⁴

8How it runs in Seal.

Seal keeps a recall as one case, from the initiating signal and health hazard evaluation through affected lots, genealogy, distribution, consignee responses, reconciliation, status reports and termination. The evaluation records severity, probability, vulnerable populations and uncertainty, and the company’s proposed classification stays separate from the authority’s decision. Each consignee is tracked from notification to closure, and quantities are kept as a running balance rather than recounted for each status report.

The signal often starts as a complaint, which keeps the original report as received. Neil, Seal’s AI agent, can trace a material lot to the downstream batches its recorded consumption reaches and flag unresolved links; recorded consumption identifies candidates, and it does not by itself establish a defect or authorise a recall.

References

121 CFR 7.3, Definitions, paragraphs (f) to (m), eCFR. https://www.ecfr.gov/current/title-21/section-7.3 (read 8 November 2026)
221 CFR 7.46, Firm-initiated recall, eCFR. https://www.ecfr.gov/current/title-21/section-7.46 (read 8 November 2026)
321 CFR 7.50, Public notification of recall, eCFR. https://www.ecfr.gov/current/title-21/section-7.50 (read 8 November 2026)
4Recalls Background and Definitions, FDA, content current as of 20 March 2026. https://www.fda.gov/safety/industry-guidance-recalls/recalls-background-and-definitions (read 8 November 2026)
5Public Warning and Notification of Recalls Under 21 CFR Part 7, Subpart C, guidance for industry and FDA staff, FDA, February 2019. https://www.fda.gov/media/110457/download (read 8 November 2026)
6EudraLex Volume 4, EU GMP Chapter 8, Complaints, Quality Defects and Product Recalls, paragraphs 8.21, 8.22, 8.29 and 8.30, European Commission, 13 August 2014. https://health.ec.europa.eu/document/download/b1eb2292-cb0d-4e3f-aea9-e3fe79faf6e3_en?filename=2014-08_gmp_chap8.pdf (read 8 November 2026)
721 CFR 806.10, Reports of corrections and removals, paragraphs (a) and (b), eCFR. https://www.ecfr.gov/current/title-21/section-806.10 (read 8 November 2026)
8openFDA drug enforcement reports D-0788-2026, D-0079-2027 and D-0713-2026, with their recall initiation and center classification dates, FDA, data last updated 28 October 2026. https://api.fda.gov/drug/enforcement.json?search=recall_number.exact:(%22D-0788-2026%22+%22D-0079-2027%22+%22D-0713-2026%22)&limit=5 (read 8 November 2026)
9Regulatory Procedures Manual, Chapter 7, Recall Procedures, version 10, FDA, July 2021, sections 7-6-1 to 7-6-3 and Attachment D. https://www.fda.gov/media/71814/download (read 8 November 2026)
1021 CFR 7.49, Recall communications, paragraphs (b) and (c), eCFR. https://www.ecfr.gov/current/title-21/section-7.49 (read 8 November 2026)
11openFDA drug enforcement reports, FDA, data last updated 28 October 2026, counted by classification for report dates from 1 January 2024. https://api.fda.gov/drug/enforcement.json?search=report_date:%5B20240101+TO+20261231%5D&count=classification.exact (read 8 November 2026)
1221 CFR 7.41, Health hazard evaluation and recall classification, eCFR. https://www.ecfr.gov/current/title-21/section-7.41 (read 8 November 2026)
1321 CFR 7.42, Recall strategy, eCFR. https://www.ecfr.gov/current/title-21/section-7.42 (read 8 November 2026)
1421 CFR 314.81, Other postmarketing reports, paragraph (b)(1), applied to ANDAs by 314.98(b), eCFR. https://www.ecfr.gov/current/title-21/section-314.81 (read 8 November 2026)
1521 CFR 7.53, Recall status reports, eCFR. https://www.ecfr.gov/current/title-21/section-7.53 (read 8 November 2026)
1621 CFR 7.55, Termination of a recall, eCFR. https://www.ecfr.gov/current/title-21/section-7.55 (read 8 November 2026)
1721 CFR 211.150, Distribution procedures, paragraph (b), eCFR. https://www.ecfr.gov/current/title-21/section-211.150 (read 8 November 2026)
1821 CFR 7.59, General industry guidance, eCFR. https://www.ecfr.gov/current/title-21/section-7.59 (read 8 November 2026)
19Investigations Operations Manual 2026, Chapter 7, Recall Activities, sections 7.3.1 and 7.3.1.1, FDA. https://www.fda.gov/media/166535/download (read 8 November 2026)
20kdc/one Chatsworth, Inc., warning letter 320-26-124, MARCS-CMS 733205, FDA, 8 September 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kdcone-chatsworth-inc-733205-09082026 (read 8 November 2026)
21IsoTis OrthoBiologics, Inc., warning letter CMS #723370, Center for Devices and Radiological Health, FDA, 24 February 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/isotis-orthobiologics-inc-723370-02242026 (read 8 November 2026)
22International Medication Systems Limited, warning letter 320-26-99, MARCS-CMS 727560, FDA, 2 July 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-medication-systems-limited-727560-07022026 (read 8 November 2026)
23Management and classification of reports of suspected quality defects in medicinal products and risk-based decision-making, Compilation of Union Procedures, European Commission, adopted 20 April 2026, section 4.3 and Appendix 1, Part III. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/management-classification-reports-suspected-quality-defects-medicinal-products-risk-based-decision-making_en.pdf (read 8 November 2026)
24A Guide to Defective Medicinal Products, Defective Medicines Report Centre, MHRA, February 2026. https://assets.publishing.service.gov.uk/media/698f286b43eb912f2e15b3fd/DMRC_Guide-to-Defective-Medicinal_Products-Feb2026.pdf (read 8 November 2026)
25Management of rapid alerts arising from quality defects risk assessment, Compilation of Union Procedures, European Commission, adopted 20 April 2026, section 5.2.4. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/management-rapid-alerts-arising-quality-defects-risk-assessment_en.pdf (read 8 November 2026)

AQuestions and answers

Who decides the recall class, the firm or FDA?

FDA. The firm gives its own risk evaluation and proposed strategy when it notifies the district, and FDA’s health hazard evaluation committee and recall unit assign the class. The firm need not wait for the classification before starting the recall.

Can FDA order a drug recall?

Not for most drugs. Part 7 recalls are voluntary, though FDA can request one. FDA’s recall manual lists order or mandatory recall authority for named products, including biological products licensed under the PHS Act that present an imminent or substantial hazard, controlled substances, medical devices, HCT/Ps, infant formula, tobacco and food, and a consent decree can also require a recall.

What do recall effectiveness check levels A to E mean?

They set how many consignees at the recall depth are contacted to confirm they received the notice and acted on it: Level A is all of them, Level B more than 10% but fewer than all, Level C 10%, Level D 2% and Level E none.

Is there a Class 4 recall?

Not in the US, where FDA uses three classes. In the UK, MHRA’s Class 4 is a Caution in Use notification rather than a recall, used for minor defects such as packaging or printed material problems, or when supply concerns mean a defective product cannot be recalled.

Does a market withdrawal have to be reported to FDA?

Part 7 asks firms to notify FDA when they remove product they believe is violative. For a removal the firm believes is a market withdrawal, it should consult FDA when the reason is unclear but complaints or adverse reactions show a deficiency. Market withdrawals are not listed in the Enforcement Report. Other duties still apply, such as a field alert for an NDA or ANDA quality problem.